Last reviewed · How we verify
Remifentanil, propofol and citanest
This is a combination of three anesthetic agents that work synergistically to induce and maintain general anesthesia through different mechanisms.
This is a combination of three anesthetic agents that work synergistically to induce and maintain general anesthesia through different mechanisms. Used for Induction and maintenance of general anesthesia for surgical procedures.
At a glance
| Generic name | Remifentanil, propofol and citanest |
|---|---|
| Sponsor | University of Aarhus |
| Drug class | General anesthetic combination |
| Target | Mu opioid receptor (remifentanil); GABA-A receptor (propofol); Voltage-gated sodium channels (prilocaine) |
| Modality | Small molecule |
| Therapeutic area | Anesthesiology |
| Phase | FDA-approved |
Mechanism of action
Remifentanil is an opioid agonist that provides analgesia and sedation by binding to mu opioid receptors. Propofol is a sedative-hypnotic that enhances GABA-mediated inhibition in the central nervous system. Prilocaine (citanest) is a local anesthetic that blocks sodium channels in nerve membranes. Together, they provide rapid induction and maintenance of general anesthesia with analgesia.
Approved indications
- Induction and maintenance of general anesthesia for surgical procedures
Common side effects
- Respiratory depression
- Hypotension
- Bradycardia
- Nausea and vomiting
- Injection site pain
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Remifentanil, propofol and citanest CI brief — competitive landscape report
- Remifentanil, propofol and citanest updates RSS · CI watch RSS
- University of Aarhus portfolio CI